| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $234,557,544 ) (Continued on the next page) |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA251591 | Predicting sensitivity and resistance in RET-driven cancers | 001 | 5 | NIH | 5/22/2025 | $40,489 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31HL182129 | Understanding how appropriate apoptotic cell degradation ensures lung homeostasis | 001 | 1 | NIH | 8/7/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA251591 | Predicting sensitivity and resistance in RET-driven cancers | 000 | 5 | NIH | 3/17/2025 | $364,399 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F31HL182129 | Understanding how appropriate apoptotic cell degradation ensures lung homeostasis | 000 | 1 | NIH | 8/7/2025 | $49,538 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32GM157939 | Cytoskeletal organization by Toll-like receptors during epithelial morphogenesis | 001 | 1 | NIH | 7/28/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | F32GM157939 | Cytoskeletal organization by Toll-like receptors during epithelial morphogenesis | 000 | 1 | NIH | 7/28/2025 | $81,040 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297011 | Targeting the evolving immunopeptidome of metastatic colorectal cancer | 000 | 1 | NIH | 2/13/2025 | $154,642 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35CA304457 | Understanding and Targeting Aberrant RNA Splicing in Leukemia | 000 | 1 | NIH | 8/15/2025 | $1,034,176 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R33CA277833 | Reducing the chasm in behavioral health care for older adults with cancer: Development of the Center for Implementation Research in Cancer in Later Life (CIRCL) | 000 | 3 | NIH | 8/18/2025 | $743,641 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA304010 | Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal Cancer | 000 | 1 | NIH | 8/15/2025 | $730,398 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R33CA302491 | Programmable nucleic acid cytometry for unraveling heterogeneity in tumors and therapies | 000 | 1 | NIH | 8/20/2025 | $418,176 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 001 | 6 | NIH | 5/28/2025 | $37,559 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA250917 | Origins and functions of pancreatic cancer-associated fibroblasts | 000 | 6 | NIH | 3/12/2025 | $338,027 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA276804 | Targeting Pancreatic Cancer Senescence with ImmunoPET | 000 | 2 | NIH | 2/28/2025 | $148,282 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35CA305347 | Overcoming Resistance to Targeted Therapy in Breast Cancer | 000 | 1 | NIH | 8/19/2025 | $1,056,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA294307 | Pilot Feasibility of DESCANSO: Cognitive Behavioral Therapy for Latino Cancer Patients to Treat the Symptom Cluster Depression, Insomnia and Fatigue | 000 | 1 | NIH | 8/13/2025 | $403,822 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01AI187249 | Role of the Cell Death Machinery in a Somatic Autoinflammatory Syndrome | 000 | 1 | NIH | 8/21/2025 | $3,066,524 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | RF1AG065396 | Toward development of senolytic CAR T cells | 000 | 6 | NIH | 8/20/2025 | $3,326,400 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA276804 | Targeting Pancreatic Cancer Senescence with ImmunoPET | 001 | 2 | NIH | 8/1/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG3CA290241 | CD28-KITv CAR T cells with PD-1 dominant negative receptor | 000 | 2 | NIH | 2/13/2025 | $1,413,307 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297013 | Developing and Validating Prognostic Models for Black women with Endometrial Cancer following Hysterectomy | 000 | 1 | NIH | 2/13/2025 | $132,825 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01EB033000 | Multicolor PET to interrogate cancer biology | 001 | 3 | NIH | 8/28/2025 | $67,312 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01EB033000 | Multicolor PET to interrogate cancer biology | 000 | 3 | NIH | 3/20/2025 | $605,806 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG3CA290241 | CD28-KITv CAR T cells with PD-1 dominant negative receptor | 001 | 2 | NIH | 5/22/2025 | $157,035 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | T32CA009207 | Investigational Cancer Therapeutics Training Program (ICTTP) | 002 | 47 | NIH | 8/8/2025 | $59,553 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288880 | Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer | 001 | 2 | NIH | 5/26/2025 | $40,260 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288880 | Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer | 000 | 2 | NIH | 3/12/2025 | $362,340 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 002 | 2 | NIH | 7/15/2025 | -$116,356 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA297030 | Metabolically Reprogramming Hepatic Macrophages to Conquer Immune Desert Tumors | 000 | 1 | NIH | 2/25/2025 | $145,336 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K08DK132518 | Control of Intestinal Epithelial Function through Lymphatic-Intestinal Stem Cell Communication | 001 | 4 | NIH | 2/25/2025 | $167,617 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 001 | 2 | NIH | 6/17/2025 | $0 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA292178 | Targeting Chromosomal Instability in the Evolution of Resistance to Matched Therapies Against Colorectal Cancer to Extend Treatment Response | 000 | 1 | NIH | 2/24/2025 | $205,700 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | K99CA279651 | Developing a communication support intervention for cancer caregivers in emerging and young adulthood | 000 | 2 | NIH | 2/18/2025 | $135,224 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R21CA299070 | Electronic Nose Technology to Predict and Assess Pathologic Response After Neoadjuvant Therapy and Recurrence for Non-Small Cell Lung Cancer | 000 | 1 | NIH | 6/16/2025 | $452,540 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA297080 | TYK2 Fusions in Lymphoma | 000 | 1 | NIH | 8/28/2025 | $3,111,184 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01AG077921 | Impact of the aging niche on cancer phenotypes probed using mouse cancer models produced by somatic engineering. | 001 | 5 | NIH | 8/18/2025 | $507,444 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 001 | 2 | NIH | 3/17/2025 | $501,086 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA288692 | HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted ADC therapy in urothelial carcinoma | 002 | 2 | NIH | 5/22/2025 | $55,676 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R35GM158422 | Mechanisms of Lipid Droplet Protein Targeting | 000 | 1 | NIH | 8/1/2025 | $440,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290400 | Investigating hypoxia as a determinant of malignant fates in pancreas cancer | 000 | 2 | NIH | 3/3/2025 | $625,610 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA290400 | Investigating hypoxia as a determinant of malignant fates in pancreas cancer | 001 | 2 | NIH | 5/26/2025 | $69,512 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 001 | 4 | NIH | 5/22/2025 | $45,703 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA258622 | Ferroptosis and Cancer Cell Signaling | 000 | 4 | NIH | 3/20/2025 | $411,339 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | UG1HL069315 | BMT Core - MSK | 001 | 25 | NIH | 7/16/2025 | $264,000 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R01CA293974 | Practical Randomized Controlled Trial of Artificial Intelligence for Melanoma Diagnosis (PRACTA-MEL) | 000 | 1 | NIH | 3/11/2025 | $700,611 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | U01HG012103 | Deciphering the Genomics of Gene Network Regulation of T Cell and Fibroblast States in Autoimmune Inflammation | 001 | 5 | NIH | 7/28/2025 | $1,254,399 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R37CA259177 | Molecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene. | 000 | 5 | NIH | 3/19/2025 | $469,069 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R50CA305244 | Instituting NCI-funded thyroid and head and neck cancer studies | 000 | 1 | NIH | 9/2/2025 | $201,870 |
| | 2025 | 2025 | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 1275 YORK AVE | NEW YORK | NY | 10065-6007 | NEW YORK | USA | R33CA274717 | Mobile phone-based deep learning algorithm for oral lesion screening in low-resource settings | 001 | 3 | NIH | 9/17/2025 | $21,816 |
|
